Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Conditions
Brief summary
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma or leukemia. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma or leukemia may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.
Detailed description
PRIMARY OBJECTIVE: I. To evaluate the impact of social-environmental risk factors on changes in Charlson Comorbidity Index over time for adolescent and young adult cancer survivors. OUTLINE: This is an observational study. Patients complete questionnaires and undergo collection of blood samples on study.
Interventions
Non-interventional study
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient must be \>= 18 years of age at the time of registration * Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL) or leukemia (acute lymphoblastic leukemia \[ALL\] only) * Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration * Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma or leukemia (ALL) must have been within 3 years prior to registration * NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach * Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3 * Patient must be English speaking in order to be able to complete the required QOL forms on this study * NOTE: Sites cannot translate the associated QOL forms * Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma or leukemia * Patient must have internet access through computer, tablet, or smartphone * Patient must have email address * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of social-environmental risk factors on changes in Charlson Comorbidity Index (CCI) | Through Study Completion, up to 2 years. | Will fit Conway-Maxwell-Poisson mixed effects models with a log link to evaluate the impact of social-environmental risk factors on changes in CCI over time. Estimates will be reported as rate ratios (and 95% confidence intervals) on the link scale, with model-based marginal means by visit to aid interpretation on the count scale. Models will be fit by maximum likelihood using all observed visits; targeted diagnostics will assess dispersion, fit, and influence. |
Countries
United States
Contacts
ECOG-ACRIN Cancer Research Group